Print

Purpose

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.

Condition

Eligibility

Eligible Ages
Between 50 Years and 100 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

(Groups with wet AMD): - Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered Inclusion Criteria (Group with healthy eyes) - No evidence of retinal disease - Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx) - No recent eye surgery in the last 4 months - No significant cataract to interfere with the quality of the imaging

Exclusion Criteria

(All Groups): - Inability to give informed consent - Significant kidney disease - Blood pressure greater than 180/110 - Previous macular laser treatment - Inability to maintain stable fixation during OCT imaging - Visual acuity worse than 20/200

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Newly-diagnosed, untreated wet AMD This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
  • Device: Optical Coherence Tomography
Wet AMD undergoing "as-needed" treatment This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
  • Device: Optical Coherence Tomography
High-risk eyes This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
  • Device: Optical Coherence Tomography
Wet AMD undergoing a "treat and extend" strategy This group will be adults with wet AMD undergoing treatment under the "treat and extend" strategy. (The "treat and extend" strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals.
  • Device: Optical Coherence Tomography

Recruiting Locations

Casey Eye Institute, Oregon Health & Science University
Portland, Oregon 97239
Contact:
George Pacheco, COA
503-494-7398
pachecge@ohsu.edu

More Details

Status
Recruiting
Sponsor
Oregon Health and Science University

Study Contact

George Pacheco, COA
503-494-7398
pachecge@ohsu.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.